Allogene Therapeutics (Nasdaq: ALLO) announced the publication of complete Phase 1 data from its TRAVERSE study of ALLO-316, an allogeneic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE